Terns Pharmaceuticals (NASDAQ:TERN) CEO Sells $681,171.93 in Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CEO Amy Burroughs sold 14,583 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $46.71, for a total transaction of $681,171.93. Following the sale, the chief executive officer directly owned 288,976 shares in the company, valued at approximately $13,498,068.96. The trade was a 4.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Terns Pharmaceuticals Stock Up 2.8%

Terns Pharmaceuticals stock opened at $49.13 on Friday. Terns Pharmaceuticals, Inc. has a 52-week low of $1.87 and a 52-week high of $49.53. The firm has a market cap of $5.10 billion, a PE ratio of -47.70 and a beta of -0.31. The company’s 50 day moving average is $39.44 and its two-hundred day moving average is $27.23.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on TERN shares. BMO Capital Markets lifted their target price on Terns Pharmaceuticals from $35.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday, December 9th. Citizens Jmp increased their price target on Terns Pharmaceuticals from $35.00 to $57.00 and gave the company a “market outperform” rating in a research report on Thursday, December 11th. Jefferies Financial Group reiterated a “buy” rating and issued a $70.00 price objective on shares of Terns Pharmaceuticals in a research note on Wednesday, December 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Terns Pharmaceuticals in a research report on Monday, December 29th. Finally, Barclays upped their target price on shares of Terns Pharmaceuticals from $36.00 to $56.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 9th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $58.11.

Hedge Funds Weigh In On Terns Pharmaceuticals

Several large investors have recently bought and sold shares of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Terns Pharmaceuticals during the 4th quarter worth about $25,000. GAMMA Investing LLC boosted its position in shares of Terns Pharmaceuticals by 762.4% during the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock worth $35,000 after acquiring an additional 770 shares in the last quarter. Engineers Gate Manager LP purchased a new position in shares of Terns Pharmaceuticals in the 2nd quarter valued at about $41,000. iA Global Asset Management Inc. purchased a new position in shares of Terns Pharmaceuticals in the 4th quarter valued at about $43,000. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Terns Pharmaceuticals during the 2nd quarter worth about $46,000. Hedge funds and other institutional investors own 98.26% of the company’s stock.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.